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Introduction 
 
Hypertrophic cardiomyopathy (HCM) is a disease of the 
myocardium that is associated with cardiac dysfunction due 
to asymmetrical thickening of the left ventricular wall of the 
heart (Richard et al., 2003; Richard et al., 2006).  HCM is 
believed to be the most common genetic form of 
cardiovascular disease in humans and has been identified 
as the most common form of cardiac disease in the domestic 
cat (Marian & Roberts, 2001; Maron, 2002; Kittleson et al., 
1999).  Mutations in the cardiac myosin binding protein C 
(MYBPC3) gene are the most frequent genetic cause of 
HCM in humans (Richard et al., 2003), and MYBPC3 is 
currently the only gene with identified mutations causing 
HCM in cats (Meurs et al., 2005; Meurs et al., 2007).    
MYBPC3 encodes the cardiac isoform of myosin 
binding protein-C (cMyBP-C), which is found almost 
exclusively in heart muscle (Harris et al., 2002).  cMyBP-C is 
believed to play a role in cardiac contraction and structure, 
but its specific functions are not well understood (Harris et 
al., 2002).  The N-terminus of the protein contains a binding 
site for myosin, a separate binding site for actin, as well as 
three potential phosphorylation sites (Gautel et al., 1995; 
Kulikovskaya et al., 2003).  A study by Kulikovskaya et al. 
(2003) demonstrated that the degree of phosphorylation of 
cMyBP-C determines whether the N-terminal region binds to 
myosin or actin, and may thus regulate thick filament 
structure and cardiac contractility.    
 In 2005, Sadayappan et al. utilized transgenic mice in which 
the phosphorylation sites of cMyBP-C were changed to non-
phosphorylatable alanines to demonstrate that 
phosphorylation of cMyBP-C is essential for normal cardiac 
function.  These mice showed severe cardiac hypertrophy 
consistent with hypertrophic cardiomyopathy (Sadayappan 
et al., 2005).  It is possible that the inability to phosphorylate 
cMyBP-C contributed to the observed phenotype by altering 
the protein’s ability to interact with other proteins, such as 
actin and myosin.  This, however, was not investigated by 
Sadayappan et al. and is thus the focus of the proposed 
study.  Determining whether the altered cMyBP-C protein is 
capable of binding to actin and myosin may provide 
important insight into the role of cMyBP-C phosphorylation in 
normal cardiac function and may also lead to a better 
understanding of the molecular basis for hypertrophic 
cardiomyopathy.   
 
Specific Aims 
 
1. The first goal of this proposal is to use the techniques 
developed by Sadayappan et al. (2005) to create 
transgenic mice in which the three known 
phosphorylation sites of cMyBP-C, Ser-273, Ser-282, 
and Ser-302, are changed to alanine.  It is 
hypothesized that this change in the amino acid 
sequence  will  prevent  phosphorylation of cMyBP-C by 
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-regulated kinases, thus resulting in depressed 
cardiac function due to reduced interactions with actin. 
2. The second goal is to determine whether the non-
phosphorylatable cMyBP-C is able to modify thick 
filament structure and cardiac contractility by 
decreasing binding to actin thin filaments. Reduced or 
abolished interactions with actin in mice expressing 
non-phosphorylatable cMyBP-C would provide direct 
evidence for the importance of phosphorylating cMyBP-
C to regulate bonds with actin necessary for 
maintaining sarcomeric integrity and regulating cardiac 
contraction.  
 
Experimental Proposal 
 
Previous research has shown that phosphorylation of 
cMyBP-C increases the likelihood that it will bind to actin thin 
filaments (Kulikovskaya et al., 2003).  However, it is not clear 
whether phosphorylation and subsequent binding to actin 
contribute to sarcomeric integrity and cardiac contractility.  
To test the hypothesis that preventing cMyBP-C 
phosphorylation will reduce thick filament stability and 
significantly diminish binding with actin, a line of transgenic 
mice will be generated which express a version of cMyBP-C 
that cannot be phosphorylated.  The procedure for 
generating the transgenic mice will be performed as 
previously described (Sadayappan et al., 2005).  RT-PCR 
using RNA isolated from mouse cardiac cells will be used to 
obtain cDNA for mouse cMyBP-C, which will then be used to 
convert Ser-273, Ser-282, and Ser-302 to alanine.  
Additionally, a myc epitope will be incorporated in each 
cDNA for later identification of the transgenically encoded 
proteins using anti-myc monoclonal antibodies. The PCR 
product will be linked to the promoter for murine -myosin 
heavy chain, which will be used to generate multiple lines of 
transgenic mice. To ensure that no endogenous 
phosphorylatable cMyBP-C is present, the mice will be bred 
to MYBPC3 transgenic mice lacking normal cMyBP-C. 
These knockouts will be produced as described by Yang et 
al. (1998).  Wild-type mice will also be bred to the cMyBP-C 
null mice, and the offspring of this cross will serve as a 
control.   
SDS-PAGE followed by Western blot analysis will 
be performed as described by Sadayappan et al. (2005) to 
verify that the system has indeed worked and the cMyBP-C 
produced in the transgenic mice is incapable of being 
phosphorylated.  Anti-myc monoclonal antibodies will detect 
the presence of myc-tagged transgenic cMyBP-C in both the 
transgenic controls and the mice encoding non-
phosphorylatable cMyBP-C.  Additionally, anti-cMyBP-C 
monoclonal antibodies will be used to identify the 
endogenous protein in wild-type mice, which will serve as a 
second control.  The null mice should show an absence of 
both the transgenically encoded and the endogenous forms 
of the protein.  Treatment of protein extracts from the hearts 
of the mice with PKA or phosphatase should show that only 
cMyBP-C from the transgenic mice expressing the non-
phosphorylatable protein remain dephosphorylated in both 
conditions.  
 If the results are consistent with those obtained by 
Sadayappan et al. (2005), depressed cardiac function should 
be evident in the transgenic mice lacking phosphorylatable 
cMyBP-C.  To ascertain whether this may be a consequence 
of altered interactions with actin, immunoprecipitation will be 
utilized to demonstrate if the chronically dephosphorylated 
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cMyBP-C binds to actin in vivo.  This will be accomplished 
using techniques described by Kulikovskaya et al. (2003).  
First, cMyBP-C will be immunoprecipitated from cardiac cells 
from the wild-type and transgenic mice using rabbit 
polyclonal antibodies raised against the C0-C1 domains of 
the protein.  The protein-antibody complexes will then be run 
on polyacrylamide gels and probed with antibodies to actin 
obtained from Santa Cruz Biotechnology, Inc. (Kulikovskaya 
et al., 2003).  As a positive control, filamentous actin will be 
blotted with the actin antibodies.   Additionally, the cMyBP-C 
from wild-type mouse hearts will serve as another positive 
control since at least some of the endogenous protein should 
be bound to actin.  Samples from the cMyBP-C null mice will 
act as negative controls due to the fact that the cells from 
these mice are deficient of normal cMyBP-C and therefore 
no protein-actin bonds should be possible. 
 If the hypothesis is supported, then the lane on the 
blot with the non-phosphorylatable cMyBP-C should not 
show any band for actin, suggesting that the protein does 
not bind to actin thin filaments. The hypothesis may also be 
supported if a faint band for actin appears, suggesting that 
there has been a reduction in the number of interactions with 
actin.  Both of these scenarios would support the proposition 
that actin can only bind to the phosphorylated form of 
cMyBP-C, and that this interaction is essential for the 
protein’s function.  They would also provide evidence that 
cMyBP-C’s inability to bind to actin may have contributed to 
the cardiac hypertrophy and overall cardiac dysfunction 
observed in these mice.  However, if cMyBP-C from the 
transgenic mice results in a band comparable to that from 
the wild-type mice, it would imply that the perpetually 
dephosphorylated cMyBP-C binds to actin as often as the 
normal form of the protein.  Therefore, if this is the case, the 
absence of these interactions could not be implicated as a 
cause of the structural and functional abnormalities seen 
within the hearts of the transgenic mice.  
It is important to note that, since a negative result 
would support the given hypothesis, it may be necessary to 
conduct further investigations to confirm that the results are 
not a consequence of other factors besides the inability to 
phosphorylate cMyBP-C. 
 
Conclusion 
 
The proposed experiment will provide valuable information 
about the function of cardiac myosin binding protein C and 
how its function is altered due to phosphorylation and 
subsequent binding to actin.  Furthermore, it may provide 
insight into the molecular basis for hypertrophic 
cardiomyopathy, which may allow for the identification of 
prospective treatments of the disease. 
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